pHion Therapeutics is a UK based biotech delivering ground-breaking nucleic acid vaccines and therapeutics.​

​

The proprietary  RALA peptide-based drug delivery system is based on a sequence of 30 amino acids which condenses anionic cargo (RNA and DNA), irrespective of size, into nanoparticles. These nanoparticles are highly efficient at cellular entry with 100% release from the endosomes. 

 

When used in vaccines, the RALA platform can deliver multiple anionic molecules, such as mRNA, in a stealth-like way by evading detection. This generates both a potent antigen-specific CD8+ T-cell response that is ideal for therapeutic vaccines, and a long-term T-Cell and antibody memory that is ideal for prophylactic vaccines.

​

The platform has the added advantage of ease of scalability, using globally available mixing devices, options for lyophilised or liquid formulations, no use of solvents which results in a more sustainable product, and reduced wastage with >99% encapsulation of cargo. 

​

pHion’s lead product is a therapeutic vaccine against HPV driven cancers (PTX_V1), with Phase I/IIA clinical trials planned to commence in 2024.

pHion’s pipeline programs also include therapeutics against, ovarian (PTX_V5), prostate cancer (PTX _V3), and a prophylactic vaccine against Crimean-Congo Haemorrhagic Fever.

 

The company is headquartered in Belfast, Northern Ireland. invoX Pharma, an integrated global biopharmaceutical company with a diversified pipeline, is a majority shareholder of pHion Therapeutics. To learn more about invoX, visit: www.invoxpharma.com. For more information follow us on LinkedIn.

​

​